Close Menu

The Next Biotech

CDY Sales Up 72%: $100M Revenue Targets in Place

Calendar year 2016 will go down as a dynamic period of growth in the life of Cellmid (ASX: CDY), a revenue generating life sciences company with lead programs in multiple disease indications and a consumer health business which has just come into its own in the last 12 months. In fact since April, CDY has hit milestone after milestone and has thus seen its revenue growth jump by a healthy 60% to a total overall revenue figure of just over $4.5M in FY2016.

Sep 14, 2016

Canadian Pot Stocks Light Up the TSX: Is MMJ Next?

While MMJ PhytoTech (ASX:MMJ) has operations all around the globe, for its growing operations it has bunkered down in Canada and already established a solid base there. There are several reasons for this: Canada has a more advanced growing industry than anywhere in the world; its TSX listed medical marijuana stocks are gaining traction on the market and regulations are well and truly opening up.

Aug 30, 2016

ACW Starts Phase II Clinical Trials: Major Milestone Set to Unlock Value Uplift?

There are currently an estimated 50 million suffers of Alzheimer’s disease (AD) globally, the highest rate in history. The consequent costs on healthcare providers are enormous and growing. But just maybe, there could be a therapeutic solution — one that softens the symptoms of dementia, delays its onset, and most crucially, begins to chip away at reversing its debilitating effects.

Aug 24, 2016

DXB Close to Phase 2 Results: Progresses Promising CKD Product

Dimerix (ASX:DXB) has just completed its “pre-IND” consultation with US regulatory body the Food and Drug Administration (FDA) with some encouraging outcomes reported. The big news for DXB is that its intended Phase 3 DMX-200 trial will be positioned as an adjunct therapy and not a fixed dose combination therapy.

Aug 16, 2016

Medical Cannabis Stock MXC Approaching Revenue Uplift?

Having gained regulatory approval to sell its MGC Derma Anti-Aging line of Cannabidiol-based cosmetic products in the US, MGC Pharmaceuticals (ASX:MXC) recently received its first revenues under its exclusive Californian distribution deal. The first year of the deal is expected to net MXC approximately AU$1.76M – a substantial number for this $51.5M capped company that has only really been on the ASX boards for a short amount of time.

Jul 22, 2016

US Sales Unlocked for CDY: Pathway to $100M Revenue in Near Term

After generating strong sales figures across Japan and Australia for its hair loss product evolis®, Cellmid (ASX:CDY) has now taken its first step in cracking the major US market. The global hair loss market is estimated to be around US$7BN annually, with topical treatments accounting for $2.3 billion of that market.

Jul 20, 2016

New ASX Listing: $15M Capped Stock with Phase II Trialled Cancer Drug

One of the latest stocks to list on the ASX happens to have a very small market cap, but a very advanced oncology drug with early sales potential. This $15M capped stock just raised $4M as part of its entry to the ASX, and its inherent value is in a niche cancer drug named Bisantrene that was ‘lost’ in the 1990s – buried under the weight of so-called billion-dollar blockbuster drugs that better suit Big Pharma’s margins.

Jul 19, 2016

MMJ Now Licensed to Grow Medical Cannabis

There are just 32 companies in Canada that have a license to grow medical cannabis – and MMJ PhytoTech, Ltd (ASX:MMJ) has just officially joined their ranks – the first ASX listed company to do so. A licence to grow medicinal cannabis is not easy to get your hands on in Canada – over 1200 companies have tried, and over 1000 have failed or given up – indicating the stringent nature of the country’s health regulators.

Jul 5, 2016

Current Stocks